Dr. Amber N. Pepper, MD
Allergy & Immunology (Allergy & Immunology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of South Florida College of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 134
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of South Florida College of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology (Internal Medicine) Physician primary
FL license ME126769
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Tampa General Hospital Tampa, FL
Medical groups
- University Medical Service Association Inc (809 clinicians)
- Lockey Fox Ledford and Glaum MDs PA (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 134
- Services billed
- 4,217
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Professional service for multiple injections of allergen | 178 | 12 |
| Professional service for preparation and provision of 1 or more antigens | 116 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 83 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 78 | 60 |
| Administration and interpretation of patient-focused health risk assessment | 66 | 38 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluticasone Propionate Other prescribers in Tampa, FL | 59 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Tampa, FL | 45 |
| Montelukast Sodium Other prescribers in Tampa, FL | 40 |
| Ipratropium Bromide Other prescribers in Tampa, FL | 39 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Tampa, FL | 35 |
| Azelastine Hcl Other prescribers in Tampa, FL | 27 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Tampa, FL | 24 |
| Epinephrine Other prescribers in Tampa, FL | 20 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Tampa, FL | 20 |
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 77 payments worth $2,712 in total to this clinician.
| Food and Beverage | $2,024 |
|---|---|
| Travel and Lodging | $531 |
| Education | $129 |
| Consulting Fee | $28.86 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $277 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $198 |
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $94.66 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL | $55.97 |
| Amgen Inc. Sep 19, 2025 | Education in-kind | $34.00 |
| Adma Biomanufacturing LLC May 21, 2025 | Consulting Fee | $28.86 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $68,527 in research payments for these studies, mostly to the institutions running them.
- A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urtic…
Novartis Pharmaceuticals Corporation - Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Regeneron Pharmaceuticals, Inc. · Completed · NCT02612454 - A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy
Novartis Pharmaceuticals Corporation - A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
UCB SA · Completed · NCT05277571 - A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy
Novartis Pharmaceuticals Corporation - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.